Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Return on Sales (2016 - 2025)

Historic Return on Sales for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to 0.5%.

  • Viridian Therapeutics, Inc.\DE's Return on Sales rose 8889700.0% to 0.5% in Q3 2025 from the same period last year, while for Sep 2025 it was 4.27%, marking a year-over-year increase of 8463500.0%. This contributed to the annual value of 893.87% for FY2024, which is 1367600.0% down from last year.
  • As of Q3 2025, Viridian Therapeutics, Inc.\DE's Return on Sales stood at 0.5%, which was up 8889700.0% from 1343.13% recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Return on Sales ranged from a high of 0.5% in Q3 2025 and a low of 1343.13% during Q2 2025
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Return on Sales had a median value of 661.94% in 2023 and averaged 531.7%.
  • Per our database at Business Quant, Viridian Therapeutics, Inc.\DE's Return on Sales tumbled by -6495600bps in 2023 and then surged by 8889700bps in 2025.
  • Quarter analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Return on Sales stood at 135.26% in 2021, then tumbled by -222bps to 436.05% in 2022, then crashed by -113bps to 928.61% in 2023, then fell by -19bps to 1108.1% in 2024, then skyrocketed by 100bps to 0.5% in 2025.
  • Its Return on Sales stands at 0.5% for Q3 2025, versus 1343.13% for Q2 2025 and 1207.11% for Q1 2025.